Commerce.com Swings to Profit in Q2, Adopts Poison Pill
CMRC sits 24% above its 52-week low of $2.41.
Summary
Commerce.com swung to a $1.1M profit in Q2 2026 from an $8.4M loss a year ago, driven by cost cuts. The company also adopted a poison pill and hinted at a future tax benefit from releasing a valuation allowance.
Key Events · Earnings and Guidance · CMRC
-
Q2 Profit Swing
Net income of $1.1M in Q2 2026 vs. net loss of $8.4M in Q2 2025, driven by a 17% reduction in operating expenses.
-
Revenue Flat
Revenue of $84.5M in Q2 2026, essentially unchanged from $84.4M a year ago, as subscription solutions revenue dipped slightly.
-
Poison Pill Adopted
Board adopted a stockholder rights plan in April 2026, exercisable if a person or group acquires 10% or more of outstanding common stock.
-
Potential Tax Benefit
Management indicated sustained profitability may allow release of a valuation allowance on deferred tax assets, which would reduce future tax expense.
Analysis · CMRC · Technology
A sharp swing to profitability highlights Commerce.com's Q2 2026 results, with net income reaching $1.1 million compared to a net loss of $8.4 million a year ago. The turnaround was fueled by aggressive cost-cutting—operating expenses fell 17%—while revenue remained essentially flat. Separately, the company disclosed the adoption of a stockholder rights plan in April, a defensive move that could deter takeover attempts. Management also signaled that sustained profitability may allow the release of a valuation allowance on deferred tax assets, which would provide a future earnings boost. The balance sheet remains solid with $157.5 million in cash and marketable securities, enough to cover the $4.1 million convertible note maturity in October.
At the time of this filing, CMRC was trading at $2.98 on NASDAQ in the Technology sector, with a market capitalization of approximately $281.4M. The 52-week trading range was $2.41 to $5.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.